# Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

> **NCT01393483** · — · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 371 (actual)

## Conditions studied

- Esophageal Cancer
- Adenocarcinoma

## Interventions

- **OTHER:** serum and tissue mesothelin
- **OTHER:** serum and tissue mesothelin
- **OTHER:** serum and tissue mesothelin

## Key facts

- **NCT ID:** NCT01393483
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-10-22
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393483, "Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01393483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*